СОСТОЯНИЕ ОПОРНО-ДВИГАТЕЛЬНОГО АППАРАТА У ПАЦИЕНТОВС АКРОМЕГАЛИЕЙ

Несмотря на относительно небольшую распространенность акромегалии (60-70 случаев на 1 млн. жителей) данная нозология занимает особое место среди гетерогенной группы заболеваний, приводящих к поражению опорно-двигательного аппарата Медленное нарастание клинических проявлений акромегалии и как следствие, поздняя постановка диагноза, являются причиной ранней инвалидизации и преждевременной смерти пациентов. С целью повышения качества жизни и социальной адаптации пациентов на сегодняшний день очевидна необходимость выявления групп больных акромегалией, требующих дополнительной терапии остеопороза и остеоартроза Был проведен поиск медицинской литературы в библиографических базах MEDLINE и Cochrane Collaboration за период с 2000 по 2009 г Поисковый запрос формировался по ключевым словам: акромегалия, акромегалия и артропатия, остеопороз и акромегалия, МПК и акромегалия, переломы и акромегалия В настоящей статье представлены данные, касающиеся различных факторов риска развития поражения костно-суставного аппарата, динамики суставного синдрома и состояния костной ткани при акромегалии.

акромегалия, остеопороз, артропатия, костная ткань

1. Baldelli R, Dieguez C, Casanueva FF. Acromegaly: from basic research to clinical studies. Endokrynol Pol - Pol J Endocrinol 2001;52:57-79.

2. Barkan A 1997 Acromegalic arthropathy and sleep apnea. J Endocrinoll55:S41-S44.

3. Bijlsma JW, Nortier JW, Duursma SA, Croughs RJ, Bosch R, Thijssen JH 1983 Changes in bone metabolism during treatment of acromegaly. Acta Endocrinol (Copenh) 104:153-159.

4. Bluestone R Bywaters E, Hartog M, Holt PJL, Hyde S 1971 Acromegalic arthropathy. Ann Rheum Dis 30:243-258.

5. Bogazzi F, Cosci C, Sardella C, Martino E, Gasperi M. Acromegaly: effects on bone metabolism and mass. J Endocrinol Invest. 2005;28(10 Suppl):33-5.

6. Bolanowski M, Daroszewski J, Medras M, Zadrozna-Sliwka B. Bone mineral density and turnover in patients with acromegaly in relation to sex, disease activity, and gonadal function. J Bone Miner Metab (2006) 24:72-78.

7. Bolanowski M, Daroszewski J, Zatonska K, Arkowska A. Circulating cytokines in relation to bone mineral density changes in patients with acromegaly. Neuro Endocrinol Lett. 2006 Feb-Apr;27(l-2):183-8.

8. Bonadonna S, Mazziotti G, Nuzzo M, Bianchi A, Fusco A, De Marinis L, Giustina A. Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women. J Bone Miner Res. 2005 Oct;20(10):1837-44. Epub 2005 Jun 6.

9. Canalis E. Regulation of bone remodeling. In: Favus MJ, editor. Primer on the metabolic bone diseases and disorders of mineral metabolism. Ill ed., Philadelphia, Lippincott-Raven; 1996. p. 29- 34.

10. Canalis E, Mazziotti G, Giustina A, Bilezikian JP 2007 Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 18:1319-1328.

11. Chapurlat RD, Delmas PD. [Bone and hormones. Effects of growth hormone on bone tissue in adults] Presse Med. 1999 Mar 13;28(10):559-62.

12. Chiodini I, Trischitta V, Carnevale V, Liuzzi A, Scillitani A 2001 Bone mineral density in acromegaly: does growth hormone excess protect against osteoporosis? J Endocrinol Invest 24:288-291.

13. Colao A, Marzullo P, Vallone G, Marino' V, Annecchino M, Ferone D, De Brasi D, Scarpa R, Oriente P, Lombardi G 1998 Reversibility of joint thickening in acromegalic patients: an ultrasonography study. J Clin Endocrinol Metab 83:2121-2125.

14. Colao A, Cannavo, S, Marzullo P, Pivonello R, Squadrito S, Vallone G, et al. Twelve months of treatment with octreotide-LAR reduces joint thickness in acromegaly. Eur J Endocrinol. 2003;148:31-8.

15. de la Piedra C, Larranaga J, Castro N, Horcajada C, Rapado A, Herrera Pombo JL, Carbo E 1988 Correlation among plasma osteocalcin, growth hormone, and somatomedin С in acromegaly. Calcif Tissue Int 43:44^15.

16. Detenbeck L, Tressler H, O'Duffy J, Randall RV. Peripheral joint manifestations of acromegaly. Clin Orthoped. 1973;91:119-27.

17. Diamond T, Nery L, Posen S 1989 Spinal and peripheral bone mineral densities in acromegaly: the effects of excess growth hormone and hypogonadism. Ann Intern Med 111:567-573.

18. Diebold J, Batge B, Stein H, Muller-Esch G, Miiller PK, Lohrs U. Osteoporosis in longstanding acromegaly: characteristic changes of vertebral trabecular architecture and bone matrix composition. Virchows Arch A Pathol Anat Histopathol. 1991;419(3):209-15.

19. Dons RF, Rosselet P, Pastakia B, et al.: Arthropathy in acromegalic patients before and after treatment: a long-term follow-up study. Clin Endocrinol (Oxf) 1988, 28:515-524.

20. Dresner Pollak R, Karmeli F, Eliakim R, Ackerman Z, Tabb K, Rachmilewitz D. Femoral neck osteopenia in patients with inflammatory bowel disease. Am J Gastroenterol 1998; 93:1483-1490.

21. Dubreuil P, Abribat T, Broxup B, Brazeau P 1996 Long-term growth hormone-releasing factor administration on growth hormone, insulin-like growth factor-I concentrations, and bone healing in the Beagle. Can J Vet Res 60:7-13.

22. Ezzat S, Forster MJ, Berchtold P, Redelmeier DA, Boerlin V Harris AG. Acromegaly: clinical and biochemical features in 500 patients. Medicine (Baltimore) 1994; 73:233-240.

23. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab. 2000;85:526-9.

24. Gorden P, Comi RJ, Maton PN, Go VL1989 NIH Conference. Somatostatin and somatostatin analog (SMS 201-995) in treatment of hormone secreting tumors of the pituitary and gastrointestinaltract and non-neoplastic disease of the gut. Ann Intern Med 110: 35-50

25. Grainger DJ, Percival J, Chiano M, Spector TD. The role of serum TGF-P isoforms as potential markers of osteoporosis. Osteoporos Int 1999; 9:398^104.

26. Grey A, Mitnick M-A, Shapses S, Ellison A, Gundberg C, Insogna K. Circulating levels of interleukin-6 and tumor necrosis factor-a are elevated in primary hyperthyroidism and correlate with markers of bone resorption - a clinical research center study. J Clin Endocrinol Metab 1996; 81:3450-3454.

27. Halse J, Gordeladze JO 1978 Urinary hydroxyproline excretion in acromegaly. Acta Endocrinol (Copenh) 89:483^191.

28. Halse J, Gordeladze JO 1981 Total and non-dialyzable urinary hydroxyproline in acromegalics and control subjects. Acta Endocrinol (Copenh) 96:451^157.

29. Halse J, Melsen F, Mosekilde L 1981 Iliac crest bone mass and remodelling in acromegaly. Acta Endocrinol (Copenh) 97:18-22.

30. Hampel R, Rose HJ, Jahreis G, Krabbe S, Meng W, Hesse V 1990 Bone alkaline phosphatase as an activity parameter of acromegaly. Dtsch Med Wochenschr 115:363-366.

31. Ho PJ, Fig LM, Barkan AL, Shapiro В 1992 Bone mineral density of the axial skeleton in acromegaly. J Nucl Med 33:1608-1612.

32. Holt P 1981 Locomotor abnormalities in acromegaly. Clin Rheum Dis 7:689-709.

33. Jalava T, Sarna S, Pylkkanen L, Mawer B, Kanis JA, Selby P, Davies M, Adams J, Francis RM, Robinson J, McCloskey E 2003 Association between vertebral fracture and increased mortality in osteoporotic patients. J Bone Min Res. 2003; 18:1254-60.

34. Johanson NA, Vigorita VJ, Goldman AB, Slavati EA 1983 Acromegalic arthropathy of the hip. Clin Orthoped 173:130-139.

35. Kayath MJ, Vieira GH 1997 Osteopenia occurs in a minority of patients with acromegaly and is predominant in the spine. Osteoporos Int 7:226-230.

36. Kellgren JH, Ball J, Tutton GK 1952 The articular and other limb changes in acromegaly. Q J Med 21:405^123.

37. Koskinen E, Lindholm R, Nieminen R, Puranen J, Attila U 1978 Human growth hormone in delayed union and non-union of fractures. IntOrthop 1:317-322.

38. Kotzmann H, Bernecker P, Hubsch P, Pietschmann P, Woloszczuk W, Svoboda T, Geyer G, Luger A 1993 Bone mineral density and parameters of bone metabolism in patients with acromegaly. J Bone Miner Res 8:459^165.

39. Layton MW, Fudman EJ, Barkan A, Braunstein EM, Fox IH 1988 Acromegalic arthropathy: characteristics and response to therapy. Arthritis Rheum 31:1022-1027.

40. Lesse GP, Fraser WD, Farquharson R, Hipkin L, Vora JP 1998 Gonadal status is an important determinant of bone density in acromegaly ? Clin Endocrinol 48:59-65.

41. Lieberman SA, Bjorkengren AG, Hoffman AR: Rheumatologic and skeletal changes in acromegaly. Endocrinol Metab Clin North Am 1992, 21:615-631.

42. Lindsay R, Pack S, Li Z 2005 Longitudinal progression of fracture prevalence through a population of postmenopausal women with osteoporosis. Osteoporos Int 16:306 312.

43. Longobardi S, Di Somma C, Di Rella F, Angelillo N, Ferone D, Colao A, et al. Bone mineral density and circulating cytokines in patients with acromegaly. J Endocrinol Invest 1998; 21:688-693.

44. Mackie EJ, Trechsel U, Brans С 1990 Somatostatin receptors are restricted to a subpopulation of osteoblast-like cells during endochondral bone formation. Development 110:1233-1239.

45. Manolagas SC. Birth and death of bone cells: Basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 2000; 21:115-137.

46. Marazuela M, Astigarraga B, Tabuenca MJ, Estrada J, Marin F, Lucas T 1993 Serum bone Gla protein as a marker of bone turnover in acromegaly. Calcif Tissue Int 52:419^121.

47. Mazziotti G, Angeli A, Bilezikian JP, Canalis E, Giustina A 2006 Glucocorticoidinduced osteoporosis: an update. Trends Endocrinol Metab 17:144-149.

48. Mazziotti G, Bianchi A, Bonadonna S, Cimino V, Patelli I, Fusco A, Pontecorvi A, De Marinis L, Giustina A. Prevalence of vertebral fractures in men with acromegaly. J Clin Endocrin Metab. First published ahead of print September 30, 2008 as doi:10.1210/ jc.2008-0791.

49. Mundy G.R. Bone-resorbing cells. In: Favus MJ, editor. Osteoporosis. Fundamentals of clinical practice. Lippincott-Raven, Philadelphia, New York; 1997. p. 17-24.

50. Naganathan V, Jones G, Nash P, Nicholson G, Eisman J, Sambrook PN 2000 Vertebral fracture risk with long-term corticosteroid therapy: prevalence and relation to age, bone density, and corticosteroid use. Arch Intern Med 2000 160: 2917-2922.

51. Ohlsson C, Bengtsson В A, Isaksson OG, Andreassen TT, Slootweg MC. Growth hormone and bone. Endocr Rev. 1998 Feb;19(l):55-79.

52. Oyamada I, Palka J, Schalk EM, Takeda K, Peterkofsky В 1990 Scorbutic and fasted guinea pig sera contain an insulin-like growth factor-I-reversible inhibitor of proteoglycan and collagen synthesis in chick embryo chondrocytes and adult human skin fibroblasts. Arch Biochem Biophys 276:85-93

53. Pfeilschifter J, Koditz R Pfohl M, Schatz H. Changes in proinflammatory cytokine activity after menopause. Endocr Rev 2002;23:90-119.

54. Podgorski M, Robinson B, Weissberger A, Stiel J, Wang S, Brooks PM 1988 Articular manifestations of acromegaly. Aust N Z J Med 18:28-35

55. Reeve J, Lunt M, Felsenberg D, Silman AJ, Scheidt-Nave C, Poor G, Gennari C, Weber K, Lorenc R, Masaryk P, Cannata JB, Dequeker J, Reid DM, Pols HA, Benevolenskaya LI, Stepan JJ, Miazgowski T, Bhalla A, Bruges Armas J, Eastell R, Lopes-Vaz A, Lyritis G, Jajic I, Woolf AD, Banzer D, Reisinger W, Todd CJ, Felsch B, Havelka S, Hoszowski K, Janott J, Johnell O, Raspe HH, Yershova OB, Kanis JA, Armbrecht G, Finn JD, Go win W, O'Neill TW; European Prospective Osteoporosis Study Group 2003 Determinants of the size of incident vertebral deformities in European men and women in the sixth to ninth decades of age: the European prospective osteoporosis study. J Bone Min Res 18:1664-1673.

56. Riggs BL, Randall RV, Wahner HW, Jowsey J, Kelly PJ, SinghM 1972 The nature of the metabolic bone disorder in acromegaly. J Clin Endocrinol Metab 34:911-918

57. Roodman GD. Advances in bone biology: the osteoclast. Endocr Rev 1996; 17: 308-332.

58. Salamone LM, Whiteside T, Friberg D, Epstein RS, Kuller LH, Cauley JA. Cytokine production and bone mineral density at the lumbar spine and femoral neck in premenopausal women. Calcif Tissue Int 1998; 63:466^170.

59. Scillitani A, Chiodini I, Carnevale V, Giannatempo GM, Frusciante V, Villella M, Piled M, Guglielmi G, Di Giorgio A, Modoni S, Fusilli S, Di Cerbo A, Liuzzi A 1997 Skeletal involvement in female acromegalic subjects: the effects of growth hormone excess in amenorrheal and mestruating patients. J Bone Min Res 12:1729-1736.

60. Seeman E, Wahner HW, Offord KP, Kumar R Johnson WJ, Riggs BL 1982 Differential effects of endocrine dysfunction on the axial and the appendicular skeleton. J Clin Invest 69:1302-1309

61. Svensson J. The importance of growth hormone (GH) and GH secretagogues for bone mass and density. Curr Pharm Des. 2002;8(23):2023-32.

62. Tauchmanova L, Pivonello R, Di Somma C, Rossi R, De Martino MC, Camera L, Klain M, Salvatore M, Lombardi G, Colao A 2006 Bone demineralization and vertebral fractures in endogenous Cortisol excess: role of disease etiology and gonadal status. J Clin Endocrinol Metab 91:1779-1784.

63. Tauchmanova L, Di Somma C, Rusciano A, Lombardi G, Colao A. The role for growth hormone in linking arthritis, osteoporosis, and body composition. J Endocrinol Invest. 2007;30(6 Suppl):35-41.

64. Ueland T, Fougner SL, Godang K, Schreiner T, Bollerslev J 2006 Serum GH and IGF-I are significant determinants of bone turnover but not bone mineral density in active acromegaly: a prospective study of more than 70 consecutive patients. Eur J Endocrinol 155:709-715.

65. Van StaaTP, Laan RF, Barton IP, Cohen S, Reid DM, Cooper С 2003 Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 48:3224-3229.

66. Vestergaard P 2007 Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes a metaanalysis. Osteoporos Int 18:427-444.

67. Waine H, BennetGA, Bauer W 1945 Joint disease associated with acromegaly. Am J Med Sci 209:671-678

68. Woodhouse LJ, Mukherjee A, Shalet SM, Ezzat S. The influence of growth hormone status on physical impairments, functional limitations, and health-related quality of life in adults. Endocr Rev. 2006 May;27(3):287-317. Epub 2006 Mar 16.

69. Zgliczynski W, Kochman M, Misiorowski W, Zdunowski P 2007 In acromegaly, increased bone mineral density (BMD) is determined by GH-excess, gonadal function and gender. Neuroendocrinol Lett 28:621-628.

70. Zofkova I. Pathophysiological and clinical importance of insulin-like growth factor-I with respect to bone metabolism. Physiol Res. 2003;52(6):657-79.